X

Stay Connected

Sign Up for Updates

network1.png

PPA strives to improve patient health, advance medical innovation and fuel economic growth.

LEARN MORE
network1.png

The PhRMA Foundation supports the research and career endeavors of scientists in drug discovery and development.

LEARN MORE
network1.png

Access Better Coverage educates consumers about the ABCs of health coverage and access to medicines.

LEARN MORE
network1.png

We Work For Health aims to increase awareness by uniting workers throughout the industry.

LEARN MORE
network1.png

Patent protection should always be considered by an inventor during the initial stages of their invention.

LEARN MORE
logo_white_MyOldMeds-New-1.png

Working to spread awareness and education about the importance of secure drug disposal.

LEARN MORE
LTAC_NEW21.png

Many Americans are struggling to afford their medicines and have important questions about their medicine costs. Let's Talk About Cost addresses these questions.

LEARN MORE
logo_white_LTAM.png

There are a lot of conversations in Washington about how to change Medicare Part D, but they aren't always focused on what seniors care about most: affordability and predictability.

LEARN MORE
 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.
Kevin Haninger

Kevin Haninger Kevin Haninger, PhD, is Vice President, International Advocacy at the Pharmaceutical Research and Manufacturers of America (PhRMA). Kevin leads PhRMA’s international health policy advocacy including development of strategy, analysis, and policy positions on the cost and value of medicines, government pricing and reimbursement, and health technology assessment. Prior to joining PhRMA, Kevin was Senior Economist in the Office of the Secretary at the U.S. Department of Health and Human Services.

Recent Posts

Setting the record straight on international reference pricing

By Kevin Haninger  |    July 16, 2019
There’s been a lot of talk in Washington about how to help patients better access and afford their medicines. These are important discussions that will hopefully result in real affordability...   Read More

New analysis shows that more medicines worldwide are available to U.S. patients

By Kevin Haninger  |    June 5, 2018
In the past year, we have seen revolutionary new treatments become available to patients in the United States for cancer and other debilitating diseases. A new analysis puts in perspective the...   Read More

In the OECD other health care services will be ten times prescription medicine spending growth over next decade

By Kevin Haninger  |    June 14, 2017
Now more than ever, innovative therapies are transforming care and providing cures for patients fighting life-threatening diseases.  In the midst of this medical progress, other health care...   Read More

Foreign government price setting by any name harms innovation and access to medicines

By Kevin Haninger  |    June 6, 2017
In an effort to contain health care spending, some foreign governments mandate prices for innovative medicines at levels below the value they provide to patients, health care systems, and the wider...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates

Trending Posts

Most Popular Posts

Pharmaceutical Research and Manufacturers of America®
950 F Street, NW Suite 300, Washington, DC 20004

Please be advised that this page contains pixel tags. To learn more about what pixel tags are, why and how
we and third parties use pixel tags, and how that use affects you, visit our privacy policy and review
"1. Information Collection."